Critical link in cell death pathway revealedJuly 23, 2009The role of a protein called XIAP in the regulation of cell death has been identified by Walter and Eliza Hall Institute researchers and has led them to recommend caution when drugs called IAP inhibitors are used to treat cancer patients with underlying liver conditions. A team led by Professor Andreas Strasser from the institute's Molecular Genetics of Cancer division has found that XIAP (X-chromosome-linked inhibitor of apoptosis protein) is the critical factor that determines which of two pathways will be followed to culminate in a cell's death. Programmed cell death (also called apoptosis) removes unwanted and dangerous cells from our bodies, protecting us against cancer development and diseases where the immune system attacks the body's own tissues, such as in insulin-dependent diabetes. This cell death process is activated by proteins on the surface of cells. The most prominent of these cell surface proteins is FAS, but curiously it does not always activate apoptosis the same way, Professor Strasser said. "One of the things that's very curious about FAS is that, depending on the cell type, the way the killing of the cell happens is substantially different," he said. "In so-called type I cells, such as lymphocytes (white blood cells involved in the immune response), the killing is very direct. When FAS is activated a protein-destroying enzyme called caspase-8 is recruited and activated, leading to activation of other enzymes (effector caspases) and rapid cell demolition," Professor Strasser said. "But in so-called type II cells, which include hepatocytes (liver cells) and pancreatic β-cells (the cells that produce insulin), that direct pathway is not sufficient to kill the cells; amplification of the apoptosis signalling pathway is required." Professor Strasser, with Drs Philipp Jost and Thomas Kaufmann (a former post-doctoral researcher from the institute who is now running his own lab in Bern, Switzerland) as well as with colleagues from St Vincent's Institute of Medical Research, LaTrobe University and the Institute of Molecular Medicine and Cell Research in Germany, has found that the protein XIAP is the discriminating factor between type I and type II FAS-induced cell death signaling. The research has been published today in the international journal Nature. For death to occur in type II cells, caspase-8 must activate the death-promoting protein called BID. Without this activation of BID the cells don't die. But the experiments of Professor Strasser's team revealed that when the gene that produces XIAP is turned off or if the XIAP protein is pharmacologically blocked, hepatocytes or pancreatic β-cells (both type II cells) will die in a type I manner; that is: independent of the presence of BID. Professor Strasser said that the finding had implications for cancer patients with underlying liver conditions who were being treated with IAP inhibitors. These inhibitors would block the production of XIAP, thereby interfering with the normal cell death pathway for liver cells and increasing the likelihood of healthy liver cells being killed, he said. The research would also be of interest to gastroenterologists as in several chronic liver diseases activation of FAS is thought to contribute to cell destruction, he said. Walter and Eliza Hall Institute |
|||||||||||||||||||||
| Related Cell Death Current Events and Cell Death News Articles New understanding about mechanism for cell death after stroke leads to possible therapy Scientists at the Brain Research Centre, a partnership of the University of British Columbia Faculty of Medicine and Vancouver Coastal Health Research Institute, have uncovered new information about the mechanism by which brain cells die following a stroke, as well as a possible way to mitigate that damage. Sweet -- sugared polymer a new weapon against allergies and asthma Scientists at Johns Hopkins and their colleagues have developed sugar-coated polymer strands that selectively kill off cells involved in triggering aggressive allergy and asthma attacks. UAB Researchers Discover Antibody Receptor Identity, Propose Renaming Immune-System Gene Researchers at the University of Alabama at Birmingham (UAB) have uncovered the genetic identity of a cellular receptor for the immune system's first-response antibody, a discovery that sheds new light on infection control and immune disorders. Inhibition of GRK2 is protective against acute cardiac stress injuries Inhibition of a protein known to contribute to heart failure also appears to be protective of the heart in more acute cardiac stress injury, namely ischemia reperfusion. Researchers find potential treatment for Huntington's disease Investigators at Burnham Institute for Medical Research (Burnham), the University of British Columbia's Centre for Molecular Medicine and Therapeutics and the University of California, San Diego have found that normal synaptic activity in nerve cells (the electrical activity in the brain that allows nerve cells to communicate with one another) protects the brain from the misfolded proteins associated with Huntington's disease. Research reveals lipids' unexpected role in triggering death of brain cells The lipid that accumulates in brain cells of individuals with an inherited enzyme disorder also drives the cell death that is a hallmark of the disease, according to new research led by St. Jude Children's Research Hospital investigators. Cornell researchers identify a weak link in cancer cell armor The seeming invincibility of cancerous tumors may be crumbling, thanks to a promising new gene therapy that eliminates the ability of certain cells to repair themselves. Sponges recycle carbon to give life to coral reefs Coral reefs support some of the most diverse ecosystems on the planet, yet they thrive in a marine desert. So how do reefs sustain their thriving populations? Aileron collaborates study in Nature: Stapled peptides inhibit Notch1 transcription factor This research validates the potential for Stapled Peptides to modulate key intracellular biological targets, such as transcription factors, that have not been addressable with current small molecule or biologic drug modalities. CSHL team solves structure of NMDA receptor unit that could be drug target for neurological diseases A team of scientists at Cold Spring Harbor Laboratory (CSHL) reports on Thursday their success in solving the molecular structure of a key portion of a cellular receptor implicated in Alzheimer's, Parkinson's, and other serious illnesses. More Cell Death Current Events and Cell Death News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||